RT Journal Article
T1 Neurally adjusted ventilatory assist in patients with acute respiratory failure: study protocol for a randomized controlled trial
A1 Villar, Jesus
A1 Belda, Javier
A1 Blanco, Jesus
A1 Suarez-Sipmann, Fernando
A1 Manuel Anon, Jose
A1 Perez-Mendez, Lina
A1 Ferrando, Carlos
A1 Parrilla, Dacil
A1 Montiel, Raquel
A1 Corpas, Ruth
A1 Gonzalez-Higueras, Elena
A1 Pestana, David
A1 Martinez, Domingo
A1 Fernandez, Lorena
A1 Soro, Marina
A1 Angel Garcia-Bello, Miguel
A1 Lidia Fernandez, Rosa
A1 Kacmarek, Robert M.
A1 NAVa In Acute Resp Failure NAVIAT, 
K1 Acute respiratory failure
K1 Neurally adjusted ventilatory assist
K1 Ventilator-free days
K1 Lung-protective ventilation
K1 Assist ventilation
K1 Liberation from mechanical ventilation
K1 Pressure-support ventilation
K1 Mechanical ventilation
K1 Sedation
K1 Nava
K1 Variability
K1 Asynchrony
K1 Efficacy
K1 Scale
AB Background: Patient-ventilator asynchrony is a common problem in mechanically ventilated patients with acute respiratory failure. It is assumed that asynchronies worsen lung function and prolong the duration of mechanical ventilation (MV). Neurally Adjusted Ventilatory Assist (NAVA) is a novel approach to MV based on neural respiratory center output that is able to trigger, cycle, and regulate the ventilatory cycle. We hypothesized that the use of NAVA compared to conventional lung-protective MV will result in a reduction of the duration of MV. It is further hypothesized that NAVA compared to conventional lung-protective MV will result in a decrease in the length of ICU and hospital stay, and mortality.Methods/design: This is a prospective, multicenter, randomized controlled trial in 306 mechanically ventilated patients with acute respiratory failure from several etiologies. Only patients ventilated for less than 5 days, and who are expected to require prolonged MV for an additional 72 h or more and are able to breathe spontaneously, will be considered for enrollment. Eligible patients will be randomly allocated to two ventilatory arms: (1) conventional lung-protective MV (n = 153) and conventional lung-protective MV with NAVA (n = 153). Primary outcome is the number of ventilator-free days, defined as days alive and free from MV at day 28 after endotracheal intubation. Secondary outcomes are total length of MV, and ICU and hospital mortality.Discussion: This is the first randomized clinical trial examining, on a multicenter scale, the beneficial effects of NAVA in reducing the dependency on MV of patients with acute respiratory failure.
PB Bmc
SN 1745-6215
YR 2016
FD 2016-10-13
LK https://hdl.handle.net/10668/25212
UL https://hdl.handle.net/10668/25212
LA en
DS RISalud
RD Apr 12, 2025